Biotech · Public company · Richmond, CA, US
Sangamo Therapeutics, Inc
Ticker SGMOQ · SEC CIK 0001001233
Track this companyFree. Adds Sangamo Therapeutics, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials213 recruiting or active
Pipeline programs25From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline25
- BIVV003Phase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BusulfanPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CERE-110: Adeno-Associated Virus injection SurgeryPhase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])Phase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CERE-120: Adeno-Associated Virus Delivery of NeurturinPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Human Immunodeficiency Virus (HIV)ClinicalTrials.gov · fetched Nov 12, 2026
- PlerixaforPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SB-318Phase 2 · MPS IClinicalTrials.gov · fetched Nov 12, 2026
- SB-509Phase 2 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- SB-728-TPhase 2 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- SB-728mR-TPhase 2 · Human Immunodeficiency Virus (HIV)ClinicalTrials.gov · fetched Nov 12, 2026
- SB-913Phase 2 · Mucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- Sham (No Treatment)Phase 2 · Chronic Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
- Sham SurgeryPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ST-400 Investigational productPhase 2 · Transfusion Dependent Beta-thalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- ST-503Phase 2 · Chronic Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
- ST-920Phase 2 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CERE-110: Adeno-Associated Virus Delivery of NGFPhase 1 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CERE-120: AAV2-NTNPhase 1 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SB-FIXPhase 1 · Hemophilia BClinicalTrials.gov · fetched Nov 12, 2026
- BIVV003Blood and Lymphatic DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- SB-318Hemophilia BClinicalTrials.gov · fetched Nov 12, 2026
- SB-913Hemophilia BClinicalTrials.gov · fetched Nov 12, 2026
- ST-400Blood and Lymphatic DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- There are no disallowed treatmentsHIV-1-infectionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials21
- Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)PHASE1_PHASE2 · SUSPENDED · started Dec 4, 2025ClinicalTrials.gov NCT06980948 · fetched Nov 12, 2026
- Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.ACTIVE_NOT_RECRUITING · started Dec 21, 2021ClinicalTrials.gov NCT05145062 · fetched Nov 12, 2026
- Long-Term Follow-up of Subjects Who Were Treated With ST-920ACTIVE_NOT_RECRUITING · started Aug 16, 2021ClinicalTrials.gov NCT05039866 · fetched Nov 12, 2026
- Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXTERMINATED · started Nov 3, 2020ClinicalTrials.gov NCT04628871 · fetched Nov 12, 2026
- Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)PHASE1_PHASE2 · COMPLETED · started Jul 23, 2019ClinicalTrials.gov NCT04046224 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseasePHASE1_PHASE2 · COMPLETED · started Mar 6, 2019ClinicalTrials.gov NCT03653247 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)PHASE1_PHASE2 · COMPLETED · started Mar 29, 2018ClinicalTrials.gov NCT03432364 · fetched Nov 12, 2026
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS IPHASE1_PHASE2 · TERMINATED · started May 24, 2017ClinicalTrials.gov NCT02702115 · fetched Nov 12, 2026
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS IIPHASE1_PHASE2 · TERMINATED · started May 11, 2017ClinicalTrials.gov NCT03041324 · fetched Nov 12, 2026
- Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia BPHASE1 · TERMINATED · started Nov 15, 2016ClinicalTrials.gov NCT02695160 · fetched Nov 12, 2026
- Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected PatientsPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 10, 2016ClinicalTrials.gov NCT02500849 · fetched Nov 12, 2026
- Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAARTPHASE1_PHASE2 · COMPLETED · started Aug 1, 2014ClinicalTrials.gov NCT02225665 · fetched Nov 12, 2026
- Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-TPHASE1_PHASE2 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01543152 · fetched Nov 12, 2026
- Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-TTERMINATED · started Mar 18, 2011ClinicalTrials.gov NCT04201782 · fetched Nov 12, 2026
- Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected SubjectsPHASE1_PHASE2 · COMPLETED · started Nov 1, 2010ClinicalTrials.gov NCT01252641 · fetched Nov 12, 2026
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyPHASE2 · COMPLETED · started Nov 1, 2009ClinicalTrials.gov NCT01079325 · fetched Nov 12, 2026
- Safety and Efficacy of CERE-120 in Subjects With Parkinson's DiseasePHASE1_PHASE2 · COMPLETED · started Oct 29, 2009ClinicalTrials.gov NCT00985517 · fetched Nov 12, 2026
- Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseasePHASE2 · COMPLETED · started Nov 1, 2008ClinicalTrials.gov NCT00876863 · fetched Nov 12, 2026
- Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's DiseasePHASE2 · COMPLETED · started Nov 1, 2006ClinicalTrials.gov NCT00400634 · fetched Nov 12, 2026
- Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's DiseasePHASE1 · COMPLETED · started Jun 1, 2005ClinicalTrials.gov NCT00252850 · fetched Nov 12, 2026
- CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseasePHASE1 · COMPLETED · started Jun 1, 2004ClinicalTrials.gov NCT00087789 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026